Journal of the American Academy of Child & Adolescent Psychiatry
ARTICLESReliability of the Services for Children and Adolescents–Parent Interview
Section snippets
METHOD
A test-retest reliability study was conducted to determine whether consistent responses could be provided by respondents to the questions that comprise the instrument. Power analysis and statistical consultation indicated that 90 paired test-retest interviews would adequately test stability of responses. The six sites involved in the MTA (University of Pittsburgh, University of California at Irvine, Columbia University, University of California at Berkeley, Duke University, New York
Use and Number of Services
For the 10 service types, test-retest κ values ranged from 0.49 to 0.98, with an overall use of services κ value of 0.97 (Table 1).
Seven of the 10 κ values reflected excellent agreement, using Fleiss guidelines (>0.75), and three reflected fair to good agreement (>0.40 to <0.75). Reports of child medication, overnight stays, and parent medication achieved κ values in the 0.90 range (0.98, 1.00, and 0.93, respectively). School services, which typically have the lowest reliability, achieved a
DISCUSSION
This is the first report of the reliability of an instrument designed specifically to measure mental health and related services use within pediatric clinical trials. It suggests that parents or caregivers can reliably report services use, even to the level of specificity of dose, provider type, and dates of services use. The significance of having a reliable instrument with which to obtain these reports centers on three major issues. First, the public health significance of examining both the
REFERENCES (33)
- et al.
Prevalence of psychiatric disorders in youth across five sectors of care
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
The effects of organizational climate and interorganizational coordination on the quality and outcomes of children's service systems
Child Abuse Negl
(1998) - et al.
Outcomes of care for children and adolescents: a conceptual model
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
Outcomes of mental health care for children and adolescents: II. Literature review and application of a comprehensive model
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
The Services for Children and Adolescents–Parent Interview: development and performance characteristics
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Mental health service use in the community and schools: results from the four-community MECA study
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
The NIMH Diagnostic Interview Schedule for Children Version 2/3 (DISC 2.3): description, acceptability, prevalence rates, and performance in the MECA Study
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
National Institute of Mental Health Collaborative Multimodal Treatment Study of Children With ADHD (the MTA): design challenges and choices
Arch Gen Psychiatry
(1997) - et al.
The Child and Adolescent Services Assessment (CASA): description and psychometrics
J Emot Behav Disord
(1996) A continuum of care: more is not always better
Am Psychol
(1996)
The evaluation of a children's mental health managed care demonstration
J Ment Health Admin
A call for a mental health services research agenda for youth with serious emotional disturbance
Ment Health Serv Res
Children's mental health service use across service sectors
Health Aff (Millwood)
Assessing functional impairment and social adaptation for child mental health services research
Ment Health Serv Res
The Great Smoky Mountains Study of Youth: functional impairment and serious emotional disturbance
Arch Gen Psychiatry
Reliability of self-reported service use: test-retest consistency of children's responses to the Child and Adolescent Services Assessment (CASA)
J Child Fam Studies
Cited by (54)
Reasons Why Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Stop and Restart Taking Medicine
2018, Academic PediatricsCitation Excerpt :For the 2-, 3-, 6-, 8-, and 10-year assessment time points, medication use was based on parent responses to the Services for Children and Adolescents—Interview. This is a reliable measure of ADHD service use, including medication use.26 For the 12-year assessment time point, medication use was based on participant responses to a single question: “Are you currently taking ADHD medication?”
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication
2013, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :Secondary analyses explored alcohol and marijuana/other drug use disorders separately. In addition to original randomized assignment to treatment, two medication treatment variables were calculated from responses to the Services for Children and Adolescents–Parent Interview,57,58 administered at all assessments to collect a cumulative history of medication treatment since enrollment into the study. Detailed information about the children’s psychoactive medication over the follow-up period has been previously reported.47
Evaluating mental health service use during and after emergency department visits in a multisite cohort of Canadian children and youth
2019, Canadian Journal of Emergency MedicineExamining daily stimulant medication use and sleep in adolescents with ADHD
2024, European Child and Adolescent PsychiatryPersonality Traits in Relation to Cognitive Disengagement Syndrome and ADHD Inattention in Two Samples of Children
2024, Journal of Clinical Child and Adolescent PsychologyA Multi-Method Examination of Peer Functioning in Children with and without Cognitive Disengagement Syndrome
2024, Journal of Clinical Child and Adolescent Psychology
The MTA (Multimodal Treatment Study of Children With Attention Deficit Hyperactivity Disorder) is a cooperative treatment study performed by six independent research teams in collaboration with the National Institute of Mental Health, Rockville, MD, and the Office of Special Education Programs of the U.S. Department of Education, and the Office of Juvenile Justice and Delinquency Prevention, Department of Justice.
The SCAPI was developed through a cooperative agreement funded by the National Institute of Mental Health. It cannot be copyrighted and is in the public domain. It can be obtained online at www.jaacap.com via the Journal's Article Plus feature, where the SCAPI interview and supplementary materials are available.
Article Plus (online only) materials for this article appear on the Journal's Web site: www.jaacap.com.
Disclosure: Dr. Jensen has research grants from Janssen Pharmaceutical and McNeil Pharmaceuticals; is a consultant/advisor to Shire, Celltech, Janssen, McNeil, Pfizer, Novartis, and Lilly; and is on the Speakers’ Bureau of Phase V, CME Outfitters, and REACH. Dr. Arnold has research funding from Celgene, Shire, Lilly, Noven, Sigma Tau, Targacept, and Novartis; is a consultant/advisor to Shire, Sigma Tau, and Noven; and is on the Speakers’ Bureau of Shire, McNeil, Lilly, and Novartis.